These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 16860527)

  • 1. A new predictive and prognostic marker (ATP bioluminescence and positron emission tomography) in vivo and in vitro for delivering adjuvant treatment plan to invasive breast tumor patients.
    Loo WT; Tong JM; Cheung MN; Chow LW
    Biomed Pharmacother; 2006 Jul; 60(6):285-8. PubMed ID: 16860527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
    Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Arimidex inhibition on proliferation of human breast solid tumors measured by ATP bioluminescence.
    Tse EY; Loo WT; Cheung MN; Chow LW; Cheng CW
    Life Sci; 2004 Dec; 76(7):827-34. PubMed ID: 15581914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy: results of a retrospective analysis.
    Debled M; MacGrogan G; Brouste V; Mathoulin-Pelissier S; Durand M; Mauriac L
    Cancer; 2007 Jun; 109(11):2197-204. PubMed ID: 17450590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
    Hussein MR; Abd-Elwahed SR; Abdulwahed AR
    Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical characteristics and prognosis of breast cancer patients with vascular invasion].
    Zhao WH; Xu BH; Zhang P; Li Q; Zhao LM; Sun Y
    Zhonghua Zhong Liu Za Zhi; 2007 Feb; 29(2):137-40. PubMed ID: 17645853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TRAIL death receptor-4 expression positively correlates with the tumor grade in breast cancer patients with invasive ductal carcinoma.
    Sanlioglu AD; Korcum AF; Pestereli E; Erdogan G; Karaveli S; Savas B; Griffith TS; Sanlioglu S
    Int J Radiat Oncol Biol Phys; 2007 Nov; 69(3):716-23. PubMed ID: 17512128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A significant correlation between nuclear CXCR4 expression and axillary lymph node metastasis in hormonal receptor negative breast cancer.
    Woo SU; Bae JW; Kim CH; Lee JB; Koo BW
    Ann Surg Oncol; 2008 Jan; 15(1):281-5. PubMed ID: 17763975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is triple negative a prognostic factor in breast cancer?
    Nishimura R; Arima N
    Breast Cancer; 2008; 15(4):303-8. PubMed ID: 18369692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The importance of prognostic factors in premenopausal women with breast cancer.
    Finek J; Holubec L; Topolcan O; Elgrova L; Skalova A; Pecen L
    Anticancer Res; 2007; 27(4A):1893-6. PubMed ID: 17649790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A study on the relationship between breast cancer molecular classification and prognosis].
    Chen XS; Ma CD; Chen CM
    Zhonghua Wai Ke Za Zhi; 2008 Sep; 46(18):1400-3. PubMed ID: 19094512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Morphological profile and association of HER-2/neu with prognostic markers in breast carcinoma in Northern Pakistan.
    Sharif MA; Mamoon N; Mushtaq S; Khadim MT
    J Coll Physicians Surg Pak; 2009 Feb; 19(2):99-103. PubMed ID: 19208313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy.
    Bartlett JM; Ellis IO; Dowsett M; Mallon EA; Cameron DA; Johnston S; Hall E; A'Hern R; Peckitt C; Bliss JM; Johnson L; Barrett-Lee P; Ellis P
    J Clin Oncol; 2007 Oct; 25(28):4423-30. PubMed ID: 17906205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
    Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
    J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers.
    Liu H; Fan Q; Zhang Z; Li X; Yu H; Meng F
    Hum Pathol; 2008 Feb; 39(2):167-74. PubMed ID: 18045647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information.
    Rydén L; Landberg G; Stål O; Nordenskjöld B; Fernö M; Bendahl PO
    Breast Cancer Res Treat; 2008 May; 109(2):351-7. PubMed ID: 17636399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical implications of HER-2/neu overexpression and proteolytic activity imbalance in breast cancer.
    Swellam M; Arab LR; Bushnak HA
    IUBMB Life; 2007 Jun; 59(6):394-401. PubMed ID: 17613170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The relationship between expression of interleukin-8 and prognosis of breast cancer].
    Yao C; Wang SM; Xie D; Wu HX; Chen DY; Lin Y
    Zhonghua Wai Ke Za Zhi; 2006 Jul; 44(13):900-3. PubMed ID: 17067482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Presenting features of breast cancer differ by molecular subtype.
    Wiechmann L; Sampson M; Stempel M; Jacks LM; Patil SM; King T; Morrow M
    Ann Surg Oncol; 2009 Oct; 16(10):2705-10. PubMed ID: 19593632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estrogen receptor beta--an independent prognostic marker in estrogen receptor alpha and progesterone receptor-positive breast cancer?
    Maehle BO; Collett K; Tretli S; Akslen LA; Grotmol T
    APMIS; 2009 Sep; 117(9):644-50. PubMed ID: 19703124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.